PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer-Reference-Cited by-同舟云学术

PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer

Published:2019-08 Issue: Volume:458 Page:66-75
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Santiago-Gómez Angélica,Kedward Thomas,Simões Bruno M.,Dragoni Ilaria,NicAmhlaoibh Roisin,Trivier Elisabeth,Sabin Verity,Gee Julia M.,Sims Andrew H.^ORCID,Howell Sacha J.,Clarke Robert B.^ORCID

Funder

Fundación Alfonso Martín Escudero

Cancer Research UK

Manchester Biomedical Research Centre

Breast Cancer Now

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference53 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative;Lancet,2005

2. Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity;Simoes;Cell Rep.,2015

3. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer;Sansone;Nat. Commun.,2016

4. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy;Li;J. Natl. Cancer Inst.,2008

5. Resistance to endocrine therapy: are breast cancer stem cells the culprits?;O'Brien;J. Mammary Gland Biol. Neoplasia,2009

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting RAC1 reactivates pyroptosis to reverse paclitaxel resistance in ovarian cancer by suppressing P21‐activated kinase 4;MedComm;2024-09

2. Targeted biocompatible Zn-metal–organic framework nanocomposites for intelligent chemotherapy of breast cancer cells;Scientific Reports;2024-08-07

3. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response;EBIOMEDICINE;2024

4. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response;eBioMedicine;2024-06

5. Navigating the Intricacies of Tumor Heterogeneity: An Insight into Potential Prognostic Breast Cancer Biomarkers;Biomarker Insights;2024-01